Gilead Stock News

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new data to be presented at the European Association for the Study of the Liver (EASL) Congress 2023, June 21-

Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 1:40 PM ET Company Participants Daniel O'Day - Chairman & CEO Merdad Parsey - Chief Medical Of

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

The biotech sector remains a fertile place of innovation that can enrich an investor. Gilead has a potential oncology blockbuster, and the stock offers a sizable dividend.

Peter Lynch is often not considered a dividend investor, which is unfortunate. He has so many valuable insights into dividend stocks that can benefit us. It's just his success with 10-baggers has domi

Gilead Sciences, Inc. (NASDAQ:GILD ) Jefferies Global Healthcare Conference June 7, 2023 11:00 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Michae

Navigating the turbulent waters in the biotech space is no mean feat. With the sector's inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market approval can b

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th

Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.

Bristol Myers Squibb is a biopharmaceutical industry stalwart that pays a high dividend. Gilead Sciences' valuation is cheap, and its dividend continues to grow.

Gilead Sciences, Inc. is expected to offer 30 Abstract Presentations at the ASCO 2023 medical meeting to be held between June 2 - 6 of 2023. Product sales of Trodelvy increased by 52% to $222 million

Large-cap biotech stocks to check out in the stock market today.

Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: Jefferies Healthcare Confe

AbbVie's current headwinds are only temporary. Gilead Sciences' business remains rock-solid.